VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06873321

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Science Valley Research Institute (from the registry)
Registry
  • NCT NCT06873321
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06873321. Randomized; single masking; primary purpose prevention. Start 2024-02-24 (actual); primary completion 2025-07-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Acronym
RESOLUTION
Condition
Peripheral Arterial Disease
Condition
Venous Thormboembolism
Condition
Cardiovascular Diseases
Condition
Vascular Surgery Patient with PAD / Carotid Stenosis
Intervention (Drug)
rivaroxaban 2.5 mg bid + aspirin 100 mg
Intervention (Drug)
clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
Lead sponsor
Science Valley Research Institute (class: other)

Record details

Record id
cardio:ct-nct06873321
Content hash
616175b659a728c38accf7c651d6c0c9cb02376b097f1b87fb2131113aa42e0f